These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 31618458)

  • 21. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
    Mi W; Ye Q; Liu S; She QB
    Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells.
    Yang K; Tang XJ; Xu FF; Liu JH; Tan YQ; Gao L; Sun Q; Ding X; Liu BH; Chen QX
    Oncol Rep; 2020 Mar; 43(3):773-782. PubMed ID: 32020210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
    Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
    Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
    Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
    Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
    Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
    Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
    Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma Cells.
    Liu Y; Zheng J; Zhang Y; Wang Z; Yang Y; Bai M; Dai Y
    Neurochem Res; 2016 Oct; 41(10):2728-2751. PubMed ID: 27394418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
    Tarantelli C; Gaudio E; Arribas AJ; Kwee I; Hillmann P; Rinaldi A; Cascione L; Spriano F; Bernasconi E; Guidetti F; Carrassa L; Pittau RB; Beaufils F; Ritschard R; Rageot D; Sele A; Dossena B; Rossi FM; Zucchetto A; Taborelli M; Gattei V; Rossi D; Stathis A; Stussi G; Broggini M; Wymann MP; Wicki A; Zucca E; Cmiljanovic V; Fabbro D; Bertoni F
    Clin Cancer Res; 2018 Jan; 24(1):120-129. PubMed ID: 29066507
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of Prostate Cancer DU-145 Cells Proliferation by
    Li X; Tang Y; Yu F; Sun Y; Huang F; Chen Y; Yang Z; Ding G
    Mar Drugs; 2018 Sep; 16(9):. PubMed ID: 30208576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
    Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
    PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.